An investment firm with several offices throughout the USA recently closed a new fund and is actively seeking new investment opportunities. The firm is focused on investing in Seed to Series A rounds, with initial check sizes ranging from $2-3M, and $5-10M reserved for follow-on investment. The firm invests in global opportunities.

The firm has a broad interest in life sciences and will consider opportunities in therapeutics, medical devices, diagnostics, and computationally enabled solutions, and is open to different types of modalities and indications. However, the firm does have a strong interest in human augmentation, which includes technologies dedicated to longevity and enhancing quality of life, cognition, enhancement, etc.

The firm’s management team is comprised of entrepreneurs who have been through the investment and fundraising process – the firm seeks companies run by driven entrepreneurs (open to both first-time and serial) whom they can work together based on mutual trust. The firm prefers to lead investment rounds and seek board representation, but is open to co-investing. The firm invests in a small number of companies and seeks to have a very active, hands-on role in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital and growth equity firm making investments in life sciences will invest as early as Series A through growth transactions and is currently investing out of their first fund. The firm looks to invest between $10-20M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical device, diagnostics. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A micro VC fund focuses on Angel to Series A stage companies across various sectors, including pharmaceutical, medical device and healthcare IT. The typical investment size is no more than $500,000, but the group will syndicate with other investors for larger investments. The firm looks to make investments in US companies with markets in US and/or China.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed round and series A rounds. Historically, the fund has been active in life science companies developing synthetic organelles-based research tools, nanoparticle research reagents and devices, web-based EMR system, proprietary screening and diagnostic tests for cancer, drug authentication platform and patient recovery technologies.

The firm focuses on investments in private companies and typically invests in pre-revenue companies with strong and experienced management team. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor group focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Korea-based biopharmaceutical company that delivers life-saving and life-sustaining protein therapies and vaccines, has been dedicated to quality healthcare solutions more than half a century. The firm is open to global investment and licensing opportunities.

The firm’s R&D portfolio utilizes its expertise in plasma protein fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative therapeutics that address unmet medical needs and enhance current treatments in areas including Immunology, Hematology, rare disease, plasma protein therapies and vaccines. The firm is committed to broadening medical and scientific knowledge pertaining to its products, disease states of interest. The firm is actively looking for partners to help the firm grow the company’s businesses.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Russian venture capital firm manages a newly raised fund co-invested by the Russian Government. The firm focused mainly on Series A and B investments and a typical allocation is around $2 million. The firm is looking for investment opportunities and partnerships that would include a “Russian angle”, i.e. a certain part of development is to be carried out in Russia. The firm is looking to make 5 investments over the next year. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The firm focused mainly on breakthrough technologies in therapeutics, diagnostics, medical devices and digital health sectors, addressing unmet medical needs in Russia and globally. Therapeutic indications of primary interest include oncology, inflammation, orphan, metabolic, cardiovascular, infectious diseases and pain management. The firm focuses on companies that already entered clinical stage. The firm prefers to work with therapeutics companies that are phase I and phase II of clinical trials but will consider pre-clinical stage companies as long as they have proof-of-concept and are ready to go to clinical stage. For medical devices, diagnostics, and medical IT, the firm prefers to work companies that are in clinical phase or on the market.

The firm is flexible regarding the management team experience, but the firm will only consider Russian-based companies or foreign companies that have (or are ready to have) Russia angles – companies that seek to conduct R&D in Russia, contract manufacturing, etc. When investing in Russia-based companies, the firm can lead the rounds and act as a value-added investor by providing their local resources, and the firm will seek to take a board seat on the company’s board on a case by case basis. The firm is open to syndication as well, especially when dealing with companies that are based outside of Russia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture/life science investment arm of a global life science, and medical equipment manufacturer invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the parent company to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.